Epidemiology of urticaria in China: a population-based study-Reference-Cited by-同舟云学术

Epidemiology of urticaria in China: a population-based study

Published:2022-06-05 Issue:11 Volume:135 Page:1369-1375
ISSN:0366-6999
Container-title:Chinese Medical Journal
language:en
Short-container-title:

Author:

Li Jiaqing,Mao Dandan,Liu Shuoshuo,Liu Ping,Tian Jing,Xue Chenhong,Liu Xiaojing,Qi Ruiqun,Bai Bingxue,Nie Jianjun,Ye Siqi,Wang Yu,Li Yuye,Sun Qing,Tao Juan,Guo Shuping,Fang Hong,Wang Jianqin,Mu Qiri,Liu Quanzhong,Ding Yan,Zhang Jianzhong

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,General Medicine

Reference43 articles.

1. Guideline of chronic urticaria beyond;Fine;Allergy Asthma Immunol Res,2016

2. Consensus statement for the diagnosis and treatment of urticaria: a 2017 update;Godse;Indian J Dermatol,2018

3. The impact of chronic urticaria on the quality of life;O’Donnell;Br J Dermatol,1997

4. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life;Grob;Br J Dermatol,2005

5. Chronic urticaria: following practice guidelines;Westby;Skin Therapy Lett,2018

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effect of Placebo on Pruritus in Patients with Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials;Clinical Drug Investigation;2024-09-06

2. Beyond the classic players: Mas‐related G protein‐coupled receptor member X2 role in pruritus and skin diseases;Journal of the European Academy of Dermatology and Venereology;2024-07-23

3. Disease Control and Treatment Satisfaction in Patients with Chronic Spontaneous Urticaria in Japan;Journal of Clinical Medicine;2024-05-17

4. Evaluation of Pharmacological Treatments for Acute Urticaria: A Systematic Review and Meta-Analysis;The Journal of Allergy and Clinical Immunology: In Practice;2024-05

5. Efficacy and safety of bilastine vs. levocetirizine for the treatment of chronic idiopathic urticaria: A multicenter, double-blind, double-dummy, phase III, non-inferiority, randomized clinical trial;Chinese Medical Journal;2024-04-01